
Tale from the Crypt: Belantamab Mafodotin
OncoPharm
00:00
DREAM7 efficacy and FDA approval subgroup
John Bizarro reviews overall and subgroup PFS and OS benefits, noting the stronger effect in patients with ≥2 prior lines.
Play episode from 05:21
Transcript


